奥扎格雷钠联合低分子肝素治疗进展性脑梗死疗效观察

目的：观察奥扎格雷钠、低分子肝素钠联合应用治疗进展性脑梗死的临床疗效。方法：96例急性脑梗死患者随机分为对照组和治疗组，每组各48例。对照组采用常规治疗方法加用奥扎格雷钠80mg于250mL生理盐水中静脉滴注，2次／d，连用14d；治疗组除上述药物外，加用低分子肝素钠0．4mL皮下注射，2次／d，连用14d；治疗前及治疗14d后对两组患者的血小板、凝血常规及临床神经功能缺损程度评分（NOS）进行评定，比较疗效。结果：14d后治疗组较对照组患者的神经功能缺损程度明显降低（P〈0．05），治疗组的临床疗效明显优于对照组（P〈0．05），血小板、凝血指标均在正常范围内。结论：应用奥扎格雷钠联合低分子肝素钠治疗进展性卒中安全有效。

Clinical effects of combination therapy with sodium ozagrel and low molecular weight heparin on progressive cerebral infarction

AIM： To observe the clinical effect of combination therapy with ozagrel and low molecular weight heparin on progressive cerebral infarction. METHODS： 96 cases with acute progressive cerebral infarction were randomly divided into treatment group （48 cases） and control group （48 cases）. The control group was only administered with 80 mg sodium ozagrel, bid, for 14 days. And the treatment group was administered with 80 nag sodium ozagrel, bid, for 14 days and 0.4 mL low molecular weight heparin sodium injection, bid, for 14 days. The number of platelet, blood clotting routine and the severity of neuro-functional defect （NDS） of both groups were detected before and after 14 days treatmeat. RESULTS： After 14days treatment, the NDS of treatment group was significandy lower than that of control group （ P 〈 0.05）. The efficacy of treatment group was significantly better than that of control group （ P 〈 0.05）. Both the number of platelet and the blood coagulation time were in normal range. CONCLUSION： Sodium ozagrel combined with low molecular weight heparin sodium are an effective and safe therapy for progressive cerebral infarction.